PL1998762T3 - Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku - Google Patents

Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku

Info

Publication number
PL1998762T3
PL1998762T3 PL07753103T PL07753103T PL1998762T3 PL 1998762 T3 PL1998762 T3 PL 1998762T3 PL 07753103 T PL07753103 T PL 07753103T PL 07753103 T PL07753103 T PL 07753103T PL 1998762 T3 PL1998762 T3 PL 1998762T3
Authority
PL
Poland
Prior art keywords
solid dosage
taste masked
active ingredient
dosage forms
forms containing
Prior art date
Application number
PL07753103T
Other languages
English (en)
Inventor
Alexander Mark Schobel
Shyam Sundar Kumar Sarma Vangala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1998762T3 publication Critical patent/PL1998762T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07753103T 2006-03-16 2007-03-15 Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku PL1998762T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78318906P 2006-03-16 2006-03-16
PCT/US2007/006452 WO2007109057A2 (en) 2006-03-16 2007-03-15 Solid dosage form containing a taste masked active agent
EP07753103A EP1998762B1 (en) 2006-03-16 2007-03-15 Solid dosage form containing a taste masked active agent

Publications (1)

Publication Number Publication Date
PL1998762T3 true PL1998762T3 (pl) 2011-04-29

Family

ID=38372464

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07753103T PL1998762T3 (pl) 2006-03-16 2007-03-15 Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku

Country Status (15)

Country Link
US (2) US8986735B2 (pl)
EP (1) EP1998762B1 (pl)
JP (1) JP5242543B2 (pl)
CN (1) CN101404990B (pl)
AT (1) ATE486593T1 (pl)
AU (1) AU2007227614B2 (pl)
BR (1) BRPI0709382A2 (pl)
CA (1) CA2643944C (pl)
DE (1) DE602007010254D1 (pl)
ES (1) ES2355306T3 (pl)
MX (1) MX2008011823A (pl)
PL (1) PL1998762T3 (pl)
PT (1) PT1998762E (pl)
RU (1) RU2437657C2 (pl)
WO (1) WO2007109057A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5242543B2 (ja) * 2006-03-16 2013-07-24 ノバルティス アーゲー 味をマスキングした活性薬剤を含有する固体剤形
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2467126A1 (en) 2009-08-19 2012-06-27 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
JP6050564B2 (ja) * 2010-03-11 2016-12-21 テイカ製薬株式会社 フィルム状製剤
JP2012031164A (ja) * 2010-07-06 2012-02-16 Teika Seiyaku Kk フィルム状製剤
JP5853460B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
JP5860480B2 (ja) 2011-01-11 2016-02-16 キャプシュゲル・ベルジウム・エヌ・ヴィ プルランを含む新しい硬カプセル
BR112013031406B1 (pt) 2011-06-08 2022-02-22 Lts Lohmann Therapie-Systeme Ag Tira de filme oral comestível e seu método de preparação
KR101328350B1 (ko) 2012-02-28 2013-11-11 주식회사 서울제약 실데나필 또는 이의 약제학적으로 허용되는 염을 유효성분으로 함유하는 고미가 은폐된 약제학적 조성물
WO2013129889A2 (ko) 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
WO2015200233A1 (en) * 2014-06-24 2015-12-30 Catherine Lee Fast acting orally disintegrating film
EP3169306A1 (en) 2014-07-17 2017-05-24 Hexal Aktiengesellschaft Orodispersible film
CN104257637A (zh) * 2014-09-26 2015-01-07 天津市聚星康华医药科技有限公司 一种酮洛芬口腔速溶膜及其制备方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
US20180118747A1 (en) * 2017-01-03 2018-05-03 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine
EP3565532A4 (en) * 2017-01-04 2020-10-28 Bonayo Lifesciences Private Limited ORAL DISPERSIBLE FILM COMPOSITION
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3609476B1 (en) 2017-04-14 2025-06-04 Capsugel Belgium NV Pullulan capsules
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN108113962B (zh) * 2018-02-23 2021-06-25 成都中医药大学 一种降低含有多酚的中药口服制剂涩味的方法
EP3670489A1 (en) 2018-12-21 2020-06-24 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
US4361580A (en) 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
GB8813682D0 (en) 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5416181A (en) 1989-02-10 1995-05-16 Penford Products Company Reinforced films made from water soluble polymers
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
US5262179A (en) 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JPH0541602A (ja) 1991-08-06 1993-02-19 Fujitsu General Ltd 円偏波及び直線偏波共用一次放射器
GB9207990D0 (en) 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
TW271400B (pl) * 1992-07-30 1996-03-01 Pfizer
GB9316580D0 (en) * 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
IT1277741B1 (it) * 1995-12-28 1997-11-12 Dompe Spa Composizioni farmaceutiche parenterali contenenti sali di alchilammonio di acidi 2-arilpropionici
AUPN969796A0 (en) 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6090401A (en) 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6995190B2 (en) * 2001-03-09 2006-02-07 Veterinary Solutions Method and treatment with ketoprofen solution
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
US6419903B1 (en) 2001-08-20 2002-07-16 Colgate Palmolive Company Breath freshening film
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US20040043134A1 (en) * 2002-08-27 2004-03-04 Corriveau Christine Leclair Rolled edible thin film products and methods of making same
US7090859B2 (en) * 2002-12-13 2006-08-15 Ronald Thomas Haas Ketoprofen compositions and methods of making them
US20040208931A1 (en) * 2002-12-30 2004-10-21 Friend David R Fast dissolving films for oral administration of drugs
CA2530843A1 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
JP4563393B2 (ja) * 2003-10-24 2010-10-13 アドヒーシブズ・リサーチ・インコーポレイテッド 診断デバイス用崩壊性フィルム
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
JP5242543B2 (ja) * 2006-03-16 2013-07-24 ノバルティス アーゲー 味をマスキングした活性薬剤を含有する固体剤形
JP5784878B2 (ja) * 2007-03-07 2015-09-24 ノバルティス アーゲー 経口投与可能なフィルム

Also Published As

Publication number Publication date
EP1998762A2 (en) 2008-12-10
US8986735B2 (en) 2015-03-24
AU2007227614B2 (en) 2011-01-06
RU2008140383A (ru) 2010-04-27
ES2355306T3 (es) 2011-03-24
AU2007227614A1 (en) 2007-09-27
WO2007109057A3 (en) 2007-12-06
JP2009530291A (ja) 2009-08-27
RU2437657C2 (ru) 2011-12-27
JP5242543B2 (ja) 2013-07-24
WO2007109057A2 (en) 2007-09-27
MX2008011823A (es) 2008-10-31
CA2643944A1 (en) 2007-09-27
US20070292515A1 (en) 2007-12-20
US20150157717A1 (en) 2015-06-11
CN101404990A (zh) 2009-04-08
CN101404990B (zh) 2012-04-25
BRPI0709382A2 (pt) 2011-07-12
CA2643944C (en) 2013-11-26
ATE486593T1 (de) 2010-11-15
DE602007010254D1 (de) 2010-12-16
EP1998762B1 (en) 2010-11-03
PT1998762E (pt) 2010-11-30

Similar Documents

Publication Publication Date Title
PL1998762T3 (pl) Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku
WO2007095600A3 (en) Disintegrable oral films
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
WO2012034079A3 (en) Macrolide dosage forms
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
EP3738587A3 (en) Dosage form for insertion into the mouth
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
NZ585219A (en) Fast release solid formulation, preparation and use thereof
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
JP2010518086A5 (pl)
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
NZ592049A (en) Compositions and methods for the treatment of bowel diseases with granulated mesalamine
TW200600117A (en) Preparation for oral administration
JP2009522376A5 (pl)
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2008051527A3 (en) Sustained release of agents for localized pain management
GB2443793B (en) Product, method of manufacture and use
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
WO2005079750A3 (en) Films for use as dosage forms
BRPI0907203A2 (pt) Forma galênica para a administração de triptanos via transmucosa oral